Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
by CNBC
CNBC— Eli Lilly's Zepbound showed promise to treat obstructive sleep apnea in two late-stage trials. It's yet another reason to stay invested in the drugmaker.
CNBC—Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials. The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit it to the Food and Drug Administration mid-year.
Kiplinger—Eli Lilly Stock Surges on Demand for Weight-Loss Drugs. Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Investopedia—Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth. Eli Lilly shares jumped in early trading Tuesday as the drugmaker reported first-quarter earnings above expectations and raised full year...